

FebriDx[®]

Test to treat at the point of care.

No guessing. No waiting. FebriDx helps your customers get clarity in minutes—so they can get the right care, right away.




PRODUCT OVERVIEW

FebriDx


FebriDx is a rapid, self-contained test that uses a simple fingerstick to help differentiate between bacterial and non-bacterial acute respiratory infections. It uses dual biomarkers—MxA, which signals a viral immune response, and CRP, which rises with bacterial inflammation—to deliver trusted results after 10 minutes. No instruments, lab equipment, or readers required. FDA 510(k) cleared with 99% NPV to confidently rule out bacterial infection.¹

Type	Rapid point-of-care diagnostic test
Intended use	Differentiate bacterial vs. non-bacterial infections
Sample type	Blood sample
Time to result	After 10 minutes
Pack size	25-test kit
Regulatory status	FDA 510(k) cleared
HSA / FSA approved	Yes
Reimbursement code	PLA0442U



Accurate

Dual-biomarker (MxA + CRP) technology



Fast

Results after 10 minutes, supporting on-the-spot treatment decisions



Instrument-free

No reader, equipment, or lab processing required (fully self-contained)



FDA 510(k) cleared

99% NPV to rule out bacterial infections¹

How it works

1

Collect a fingerstick blood sample (lancet included in device)

2

Transfer the blood to the test strip via capillary action

3

Push the buffer release button


4

Read results after 10 minutes



Scan the QR code to view our in-depth instructions for use.

Result interpretation



POINT-OF-CARE INSIGHTS

Antibiotic clarity. POC-ready.



- Elevate your clinical role
Support timely, informed decisions in urgent care and emergency settings
- Help guide smarter decisions
FebriDx clarifies if symptoms are likely bacterial, supporting responsible antibiotic use
- Fast, actionable, and accessible
Test and interpret results during a single visit. No instruments or lab equipment required

Clinical power

Assess and act in one visit

Trusted results

Dual biomarkers guide treatment

POC-ready

No equipment needed, results after 10 minutes

Ideal use case

FebriDx is well-suited for test-to-treat programs in urgent care, emergency departments, and other POC environments. Use with patients presenting with:

- Cold and flu-like symptoms
- Fever, sore throat, or cough
- Nasal congestion or chest discomfort
- Shortness of breath
- Symptoms ≤ 7 days and within 3 days of fever onset

Why FebriDx fits here

FebriDx supports clinical care, drives meaningful engagement, and fits seamlessly into urgent care and emergency care workflows

Enables clinician-led test-to-treat protocols

Clinically relevant during respiratory season and year-round

Boosts provider credibility as a frontline care destination

Contact us today to place an order: 657-233-5880 | USsales@phasesci.com

FebriDx® is FDA 510(k) cleared for prescription use only. It is intended for use in patients aged 12 to 64 presenting to urgent or emergency care settings with signs and symptoms of acute respiratory infection, within seven days of symptom onset and within three days of fever onset. FebriDx results are to be used in conjunction with other clinical and diagnostic findings and are not intended as a stand-alone diagnostic tool. This test does not identify specific pathogens or determine infection severity. FebriDx is not currently available for over-the-counter sale and is not CLIA-waived. A CLIA waiver is anticipated.

1. Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic accuracy of a bacterial and viral biomarker point-of-care test in the outpatient setting. JAMA Netw Open, 2022, 5(10): e2234588.

2. U.S. Food and Drug Administration. 510(k) summary for FebriDx Bacterial/Non-Bacterial Point-of-Care Assay. K230917.

Distributed in partnership with Lumos Diagnostics.

MKT-MC-0037 V 1.0